[Antiarrhythmic action of beta-blocking agent in patients with mitral valve prolapse having premature ventricular contractions].

Journal of cardiology. Supplement Pub Date : 1989-01-01
T Shioto, K Takenaka, T Sakamoto, K Amano, J Suzuki, W Amano, H Takahashi, T Sugimoto
{"title":"[Antiarrhythmic action of beta-blocking agent in patients with mitral valve prolapse having premature ventricular contractions].","authors":"T Shioto,&nbsp;K Takenaka,&nbsp;T Sakamoto,&nbsp;K Amano,&nbsp;J Suzuki,&nbsp;W Amano,&nbsp;H Takahashi,&nbsp;T Sugimoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>To investigate the origin and evaluate the effect of one of the most potent beta blocker, carteolol, on premature ventricular contractions (PVCs) in patients with mitral valve prolapse (MVP), 21 patients (35 +/- 12 years; mean +/- SD) including 10 with PVCs were studied by simultaneous electrocardiography and echocardiography before and after intravenous injection of carteolol. In all 21 MVP patients including 10 MVP patients with PVCs, carteolol (6 micrograms/kg/2 min, i.v.) caused significant decrease in systolic and diastolic blood pressures and in heart rate. Carteolol markedly (25% or more) reduced frequency of PVCs in four of the 10 patients, but no significant changes in five, and PVCs were increased in frequency in the remaining one. However, in all 21 MVP patients, carteolol did not change left ventricular end-diastolic and end-systolic dimensions, and the degree of MVP nor mitral regurgitant areas evaluated by color Doppler echocardiography. These results were exactly the same as those of the patients with PVCs. In conclusion, intravenous injection of beta-blocker, carteolol, reduced PVCs in 40% of the MVP patients with PVCs, but this antiarrhythmic action is not related to the degree of mitral valve prolapse, or mitral regurgitation evaluated by Doppler method.</p>","PeriodicalId":77193,"journal":{"name":"Journal of cardiology. Supplement","volume":"21 ","pages":"65-72, discussion 73-4"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology. Supplement","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To investigate the origin and evaluate the effect of one of the most potent beta blocker, carteolol, on premature ventricular contractions (PVCs) in patients with mitral valve prolapse (MVP), 21 patients (35 +/- 12 years; mean +/- SD) including 10 with PVCs were studied by simultaneous electrocardiography and echocardiography before and after intravenous injection of carteolol. In all 21 MVP patients including 10 MVP patients with PVCs, carteolol (6 micrograms/kg/2 min, i.v.) caused significant decrease in systolic and diastolic blood pressures and in heart rate. Carteolol markedly (25% or more) reduced frequency of PVCs in four of the 10 patients, but no significant changes in five, and PVCs were increased in frequency in the remaining one. However, in all 21 MVP patients, carteolol did not change left ventricular end-diastolic and end-systolic dimensions, and the degree of MVP nor mitral regurgitant areas evaluated by color Doppler echocardiography. These results were exactly the same as those of the patients with PVCs. In conclusion, intravenous injection of beta-blocker, carteolol, reduced PVCs in 40% of the MVP patients with PVCs, but this antiarrhythmic action is not related to the degree of mitral valve prolapse, or mitral regurgitation evaluated by Doppler method.

[阻滞剂对二尖瓣脱垂伴室性早搏患者的抗心律失常作用]。
为了研究一种最有效的受体阻滞剂卡替洛尔对二尖瓣脱垂(MVP)患者室性早搏(PVCs)的来源和影响,21例患者(35 +/- 12岁;平均+/- SD),包括10例室性早搏患者,静脉注射卡替洛尔前后同时进行心电图和超声心动图检查。在所有21例MVP患者中,包括10例合并室性早搏的MVP患者,卡替洛尔(6微克/千克/2分钟,静脉注射)可显著降低收缩压、舒张压和心率。卡替洛尔显著(25%或更多)降低了10例患者中4例的室性早搏频率,但5例无显著变化,其余1例室性早搏频率增加。然而,在所有21例MVP患者中,卡替洛尔没有改变左心室舒张末期和收缩末期的尺寸,彩色多普勒超声心动图评估MVP程度和二尖瓣反流区域。这些结果与室性早搏患者的结果完全相同。综上所述,静脉注射β受体阻滞剂卡替洛尔可降低40%的MVP伴室性早搏患者的室性早搏,但这种抗心律失常作用与二尖瓣脱垂程度或多普勒法评估的二尖瓣反流无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信